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Insulin resistance (IR) in skeletal muscle is a key defect mediating the link between obesity and type 2 33	
diabetes, a disease that typically affects people in later life. Sarcopenia (age-related loss of muscle 34	
mass and quality) is a risk factor for a number of frailty-related conditions that occur in the elderly. In 35	
addition, a syndrome of “sarcopenic obesity” (SO) is now increasingly recognised, which is common 36	
in older people and is applied to individuals that simultaneously show obesity, IR and sarcopenia. 37	
Such individuals are at increased risk of adverse health events versus those who are obese or 38	
sarcopenic alone. However, there are no licensed treatments for sarcopenia or SO, the syndrome is 39	
poorly defined clinically and the mechanisms that might explain a common aetiology are as yet not 40	
well characterised. In this review, we detail the nature and extent of the clinical syndrome, highlight 41	
some of the key physiological processes that are dysregulated and discuss some candidate molecular 42	
pathways that could be implicated in both metabolic and anabolic defects in skeletal muscle, with an 43	
eye towards future therapeutic options. In particular, the potential roles of Akt/mammalian target of 44	




Associations between obesity, diabetes and skeletal muscle aging 47	
The International Diabetes Federation has estimated that there were 382 million people living with 48	
diabetes in 2013, with this number predicted to rise to 592 million by 2035, of which the significant 49	
majority would be of >40 years old (IDF 2013). Of these, 90% suffer from Type 2 diabetes (T2D), 50	
which is characterised by both beta-cell failure and resistance to the actions of insulin at the tissue 51	
level (insulin resistance; IR). As skeletal muscle is responsible for the majority of the body’s post-52	
prandial glucose disposal, IR in this tissue results in substantial whole body metabolic disturbances. 53	
However, it is likely that the metabolic disturbances associated with T2D are further exacerbated by 54	
the marked loss of skeletal muscle mass that can also be associated with these conditions (Kim, et al. 55	
2010; Park, et al. 2009). Specifically, loss of muscle mass induces a 2-3% decline in basal metabolic 56	
rate per decade after age 20 and 4% per decade after age 50, resulting from concomitant loss of 57	
mitochondrial volume density and oxidative capacity (Conley, et al. 2000). 58	
This loss of muscle mass in the elderly is also the principal factor responsible for “frailty”, a 59	
syndrome that has been clinically defined as the possession of three of: unintentional weight loss (10 60	
pounds (~4.5kg) in the past year), self-reported exhaustion, weakness (poor grip strength), slow 61	
walking speed and low physical activity (Fried, et al. 2001). Loss of muscle mass (atrophy) is an 62	
inevitable, although somewhat modifiable, process that occurs with aging (Sayer, et al. 2008), when it 63	
is referred to as primary sarcopenia. In contrast, secondary sarcopenia can result from reduced 64	
physical activity or pathological causes, such as cachexia associated with malnutrition, organ failure, 65	
inflammatory disease, malignancy or endocrine disease (Cruz-Jentoft, et al. 2010). Sarcopenia has 66	
been implicated as a risk factor for numerous adverse health outcomes associated with frailty, 67	
including weakness, falls and fractures, immobility, functional decline, disability and loss of 68	
independence in the elderly (Batsis, et al. 2014; Cruz-Jentoft et al. 2010). It has also been associated 69	
with increased mortality in some prospective studies (Landi, et al. 2013) but not others (Cesari, et al. 70	
2009). 71	
The concept of “sarcopenic obesity” (SO) was introduced to highlight a syndrome present in a group 72	
of older patients in whom obesity is accompanied by sarcopenia and IR (Baumgartner 2000). The 73	
prevalence of SO in a recent study of adults in the USA was estimated to be 18% of women and 42% 74	
of men of mean age ~70, with increased risks of mortality being demonstrated for either obese or 75	
sarcopenic women (Batsis et al. 2014). However, the significance of concurrent obesity and 76	
sarcopenia was really emphasised by a separate study of older people, which demonstrated a 2-3 times 77	
higher risk of developing disability associated with reduced activities of daily living in individuals 78	
with SO versus others with sarcopenia or obesity alone (Baumgartner, et al. 2004). Currently, the 79	
characterisation of SO is as yet confined to a group of clinical and epidemiological observations, 80	
rather than being underpinned by defined common mechanisms (Bollheimer, et al. 2012). 81	
Nevertheless, the apparently high prevalence of SO and its profound consequences for healthcare 82	
provision mandates that additional research is carried out into the mechanisms underpinning the 83	
syndrome, in order to establish whether the muscle loss and IR associated with SO are indeed 84	
inevitable co-morbidities and to identify more effective therapies. The recommended therapeutic 85	
interventions are confined to lifestyle changes and are of limited effect, as there are no currently 86	
licenced medications for the treatment of sarcopenia (Bouchonville and Villareal 2013). 87	
In this review, we intend to highlight potential mechanisms and pathways that might underpin both 88	
sarcopenia and IR in aging muscle, which may in the future be of interest as therapeutic targets for 89	
SO. 90	
 91	
Clinical and functional delineation of sarcopenia and sarcopenic obesity 92	
The study of sarcopenia is still hampered by a lack of consensus regarding both definitions and 93	
techniques for assessment. Various diagnostic criteria have been used in studies to date, but frequently 94	
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these have been established purely on Gaussian distributions of measurements made in the test 95	
populations (Baumgartner, et al. 1998; Janssen, et al. 2002; Newman, et al. 2003). More recently, two 96	
consensus statements have been issued aimed at defining sarcopenia objectively. The European 97	
Working Group on Sarcopenia in Older People stipulated that low muscle mass and either low muscle 98	
strength or physical performance should be present for a positive diagnosis to be made (Cruz-Jentoft 99	
et al. 2010), while the Society of Sarcopenia, Cachexia and Wasting Disorders defined “Sarcopenia 100	
with limited mobility" as lean appendicular mass/height2 of 2 SDs or more below the mean for 20-30 101	
year olds, with a walking speed of  ≤ 1m/s (Morley, et al. 2011) . 102	
In addition to the challenges of defining SO, its assessment may be confounded by unchanging or 103	
increasing body mass index in older individuals due to increased adiposity, as this will mask any 104	
coincident loss of skeletal muscle mass. Therefore, evaluation of SO necessitates the careful 105	
assessment of body composition by other methods (Muller, et al. 2012). For example, in a recent 106	
cross-sectional survey that considered risk factors for and associations with SO in Korean people >65 107	
years of age, sarcopenia was defined as weight-adjusted dual x-ray absorptiometry-determined 108	
appendicular skeletal muscle mass <2 standard deviations below the mean for healthy young adults 109	
(Ryu, et al. 2013). In the separate longitudinal Korean Sarcopenic Obesity Study, the extent of 110	
visceral obesity at the start of the study was shown to correlate with the extent of loss of appendicular 111	
muscle over ~2 years of follow-up, indicating that there may be a causal component to this 112	
association. However, baseline muscle mass was unable to predict the development of obesity (Kim, 113	
et al. 2014). 114	
A further challenge to the definition and assessment of SO is that loss of muscle strength with age is 115	
substantially more pronounced than loss of mass, suggesting that the close relationship between 116	
muscle cross-sectional area and mass in younger people is not maintained in sarcopenia (Klein, et al. 117	
2002). Moreover, this notion asserts that the loss of skeletal muscle quality is a significant contributor 118	
to age-related frailty (Goodpaster, et al. 2006). Therefore, the term “dynapenia” has been proposed as 119	
a more clinically relevant alternative to sarcopenia, to reflect the fact that loss of muscle function and 120	
mass are not reciprocally related, and that the former is more relevant to increased risk of adverse 121	
events, such as falls (reviewed in (Manini and Clark 2012)). Indeed, using a tertile-based 122	
classification of both muscle strength and adiposity in a small study population, it was shown that 123	
presence of “dynapenic obesity” but not SO was predictive of increased risk of falls (Scott, et al. 124	
2014). However, as sarcopenia and SO are the terms that are best established in clinical use (Cruz-125	
Jentoft et al. 2010), we will utilise these in this review. A general summary of the factors involved in 126	
SO is presented as Figure 1. 127	
Although numerous animal models have been established to study muscle atrophy associated with 128	
disuse (Bodine, et al. 2001a), denervation (Muller, et al. 2007), sepsis (Breuille, et al. 1998), cancer 129	
cachexia (Temparis, et al. 1994) and glucocorticoid administration (Gardiner, et al. 1980), it seems 130	
that sarcopenia associated with aging is mechanistically distinct from the acute atrophy induced by 131	
such disease processes (Edstrom, et al. 2006). Furthermore, the study of bona fide sarcopenia in 132	
animal models is hampered by the length of time animals must be housed in order to reach an age at 133	
which it is detectable (20-24 months for rodents) (Bernet, et al. 2014; Bollheimer et al. 2012; Fry, et 134	
al. 2015; Muller et al. 2007; Tardif, et al. 2014)). In addition, studies of animal models of SO 135	
demonstrating pathophysiological or molecular mechanisms pertinent to the development of the 136	
syndrome in humans have rarely been reported. However, some researchers have studied aged rats 137	
with diet-induced obesity (Bollheimer et al. 2012; Tardif et al. 2014), while obese Zucker rats are 138	
characterised by marked obesity, IR and generalised muscle atrophy (Nilsson, et al. 2013) and thus 139	
may be useful for study of SO at a younger age. 140	
 141	
Insulin resistance with respect to skeletal muscle glucose, lipid and protein metabolism 142	
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Peripheral glucose utilisation is reduced as part of the IR that develops with age (Gumbiner, et al. 143	
1992) and is substantially impaired in T2D (Cusi, et al. 2000), but protein turnover is also 144	
dysregulated. Skeletal muscle accounts for 40-50% of lean body mass in an adult human and therefore 145	
for the majority of whole body insulin-stimulated glucose disposal (Baron, et al. 1988; DeFronzo and 146	
Tripathy 2009). Thus, muscle mass is an important determinant of glucose and energy homeostasis 147	
(Wolfe 2006), and is determined by the balance between protein synthesis and breakdown in the 148	
tissue. An abundant supply of essential amino acids both inhibits proteolysis and stimulates protein 149	
synthesis (Castellino, et al. 1987; Cuthbertson, et al. 2005; Giordano, et al. 1996), while at least in 150	
younger people, insulin has a predominant effect to inhibit protein catabolism in muscle (Abdulla, et 151	
al. 2016; Fukagawa, et al. 1985; Gelfand and Barrett 1987). 152	
Insulin-mediated accretion of muscle mass has been ascribed to activation of p38 mitogen-activated 153	
protein kinase (MAPK) and mammalian target of rapamycin (mTOR)/p70S6 kinase, and thus 154	
stimulation of mRNA translation (Fujita, et al. 2007; Guillet, et al. 2004a; Kimball, et al. 1998). In 155	
humans it is most likely that these effects are mediated through enhanced amino acid availability or 156	
delivery through increased perfusion (Fujita, et al. 2006; Timmerman, et al. 2010), all of which have 157	
been reported to be impaired in aged muscle (Bell, et al. 2005; Cuthbertson et al. 2005; Groen, et al. 158	
2014; Rasmussen, et al. 2006). Thus the concept of age-related “anabolic resistance” has been 159	
proposed, to describe the reduced muscle protein synthesis that occurs in response to nutrients 160	
(Cuthbertson et al. 2005) or insulin (Fujita, et al. 2009; Rasmussen et al. 2006) and the reduced 161	
insulin-mediated suppression of proteolysis (Guillet, et al. 2004b; Wilkes, et al. 2009) that is 162	
associated with sarcopenia.  163	
Interestingly, resistance to the anabolic action of insulin has been demonstrated in older individuals of 164	
normal muscle mass, and may therefore precede the physical manifestations of sarcopenia 165	
(Rasmussen et al. 2006). Indeed, it seems that differential IR with respect to glucose, protein and lipid 166	
metabolism can develop with aging, IR and SO. For example, many older individuals are insulin 167	
sensitive with regard to glucose metabolism, but not protein synthesis (Fujita et al. 2006). However, 168	
insulin, essential amino acids and resistance exercise are all less effective at inducing increases in 169	
muscle protein synthesis with increasing adiposity (Guillet, et al. 2009; Murton, et al. 2015; Nilsson et 170	
al. 2013). Metabolite fluxes within young, normal muscle and in muscle from older SO patients are 171	
summarised in Figure 2. 172	
Adding further complexity, muscles of differing fibre type composition show contrasting sensitivity 173	
of both glucose and protein metabolism to insulin (Baillie and Garlick 1991; Lillioja, et al. 1987). 174	
T2D is characterised by reduced numbers of predominantly oxidative type I fibres relative and more 175	
glycolytic type II fibres (Oberbach, et al. 2006), with the proportion of type I fibres correlating 176	
positively with insulin sensitivity (Stuart, et al. 2013). Aging also results in a preferential reduction in 177	
the size of type II fibres (Lexell 1995), and the net result is that reduced mitochondrial activity 178	
(Johannsen, et al. 2012) and IR (Groen et al. 2014; Tardif et al. 2014) may also be evident in muscle. 179	
In summary, it appears IR, loss of muscle mass and changes in muscle fibre type all have the potential 180	
to independently or additively alter whole body glucose homeostasis with aging. 181	
Clearly, defects that impair insulin-stimulated glucose disposal into muscle and thus negatively 182	
impact on whole-body glucose homeostasis will likely be compounded by concurrent sarcopenia, as 183	
in SO. It is known that interventions aimed at increasing muscle mass counter the development of IR 184	
(Dela, et al. 1996), but it is still not fully appreciated whether this is merely due to a proportionate 185	
increase in capacity for glucose disposal, or whether metabolic adaptation works synergistically with 186	
an increase in muscle mass. Recent studies in our laboratories have illustrated the potential for a dual 187	
effect, as manipulating bioavailability of single proteins in individual muscles, for example by 188	
inhibition of myostatin (Cleasby, et al. 2014), can result in enhanced glucose disposal on a per unit 189	
mass basis in addition to increased muscle mass, and therefore an enhancement in the total capacity 190	




Possible mechanisms: Accumulation of intramyocellular lipid and intermuscular adipocytes 193	
Both aberrant adipogenesis in muscles and excess intracellular lipid deposition have been associated 194	
with impaired muscle mass and insulin sensitivity. Increased adipocyte infiltration between muscle 195	
fascicles has been associated with both impaired gait (Scott, et al. 2015) and IR (Albu, et al. 2005). 196	
Furthermore, a longitudinal study demonstrated that progressive loss of muscle mass/quality was 197	
associated with increasing intermuscular fat in both aging humans (Delmonico, et al. 2009) and rats 198	
(Tardif et al. 2014), while another recent paper has shown that cultured intermuscular adipocytes 199	
produce pro-diabetic substances, providing evidence of a causal relationship (Laurens, et al. 2015). 200	
Additionally, a mechanistic link between expansion of visceral adipose tissue and muscle atrophy has 201	
been suggested by the observation of reduced expression of contractile proteins in human myotubes 202	
co-cultured with visceral adipocytes from obese subjects (Pellegrinelli, et al. 2015). 203	
The impact of accumulation of intramyocellular lipid (IMCL) has been thoroughly studied and there 204	
is a well-established association between IMCL and  muscle IR and T2D. However, triacylglycerol, 205	
the main storage form of lipid, is not thought to be mechanistically linked with the development of IR 206	
(reviewed in (Turner, et al. 2014)). Instead, the more bioactive derivatives ceramide and 207	
diacylglycerol have direct inhibitory effects on insulin signalling and metabolism (Chibalin, et al. 208	
2008; Ussher, et al. 2010). Increased IMCL has also been associated with impaired muscle function in 209	
a number of studies. Lipid infusion results in reduced protein synthesis in response to both amino 210	
acids and insulin in healthy human volunteers (Stephens, et al. 2015), while diet-induced obesity and 211	
ectopic deposition of lipid in muscle rather than adipose tissue is also associated with impaired protein 212	
synthesis in rodents (Anderson, et al. 2008; Masgrau, et al. 2012; Tardif et al. 2014). This is 213	
associated with increased phosphorylation of elongation factor 2B, a key mediator of ribosomal 214	
protein synthesis, in rodent muscle, and a saturated fatty acid (SFA)/ceramide-induced increase in 215	
elongation factor 2α activation in cultured muscle cells (Tardif et al. 2014). However, the nature of 216	
the lipids is important, because diets enriched in the SFAs impair muscle protein synthesis in rats than 217	
those based on unsaturated fatty acids (Tardif, et al. 2011), in addition to their increased tendency to 218	
cause insulin resistance (Budohoski, et al. 1993). The effect of increased IMCL on metabolite fluxes 219	
in muscle of sarcopenic obese patients is summarised in Figure 2. 220	
  221	
Inflammation in obesity and in muscle 222	
Obesity is now recognised to be a subclinical inflammatory state, characterised by increased 223	
infiltration of adipose tissue with pro-inflammatory cell types, most notably macrophages (Lumeng, et 224	
al. 2007). Macrophage infiltration has also been demonstrated by a number of groups (Fink, et al. 225	
2014; Hevener, et al. 2007), but not all (Tam, et al. 2012), to be a feature of obesity-associated IR in 226	
skeletal muscle  and a synergistic interaction between macrophages and fatty acids that leads to 227	
impaired muscle insulin action has been reported (Varma, et al. 2009). However, an alternative 228	
proposal is that the dyslipidaemia associated with obesity activates cellular stress signalling pathways 229	
and thereby apoptosis and atrophy in skeletal muscle (Sishi, et al. 2011). In particular, SFA 230	
specifically can induce pro-inflammatory macrophage activation and consequent p38 MAPK-231	
mediated IR in cultured myotubes, an effect that is ameliorated by the UFA palmitoleate (Talbot, et al. 232	
2014). This role of p38 MAPK contrasts with its positive involvement in normal insulin-stimulated 233	
glucose disposal into muscle (Kimball et al. 1998), while in addition, loss of skeletal muscle satellite 234	
cell self-renewal is associated with impaired p38 MAPK α/β activation in aged muscle (Bernet et al. 235	
2014), implying that non-specific inhibition of this kinase is unlikely to yield overall beneficial effects 236	
in vivo. The explanation for these apparently disparate roles of p38 MAPK may be distinct functional 237	
specificities of the four identified isoforms of the kinase (Brault, et al. 2013), a possibility that has as 238	
yet not been fully investigated. 239	
Further evidence implicates the balance between M1 and M2-type macrophage levels in muscle 240	
function. Obesity is characterised by accumulation of M1-type macrophages, at the relative expense 241	
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of the M2 subtype (Lumeng et al. 2007). However, muscle expression of M1-related cytokines 242	
correlates positively with muscle mass and strength (Beenakker, et al. 2013), while M2a-type 243	
macrophages accumulate in aging muscle (Wang, et al. 2015). Thus, the shift in macrophage 244	
phenotype with aging may be in the opposite direction to that in insulin resistant muscle. 245	
Skeletal muscle inflammation is also characterised by activation of the classical signalling pathway to 246	
the transcription factor Nuclear Factor κB (NFκB). Chronic activation of this pathway causes 247	
profound atrophy in mouse muscle (Cai, et al. 2004), while correspondingly it is activated by 248	
immobilisation of muscle (Bar-Shai, et al. 2005) and targeted ablation of the NFκB activating enzyme 249	
Inhibitor κ B kinase 2 (IκK2) improves skeletal muscle strength, maintains mass and promotes 250	
regeneration (Mourkioti, et al. 2006). However, short-term muscle fibre-specific overexpression of 251	
IκK2 or the p65 subunit of NFκB, sufficient to cause atrophy, does not impair insulin-stimulated 252	
glucose disposal (Polkinghorne, et al. 2008), providing further evidence that these two phenotypes are 253	
not inextricably linked as part of a pro-inflammatory phenotype.  254	
 255	
Other molecular pathways potentially mediating the development of both sarcopenia and 256	
insulin resistance 257	
A summary of the roles of the molecules and pathways discussed here in glucose and protein 258	
metabolism is presented as Figure 3. 259	
Phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signalling 260	
Insulin and insulin-like growth factor-1 (IGF1) have predominantly metabolic and anabolic effects on 261	
muscle, respectively. However, upon binding to their cognate receptors, both exert their effects by 262	
recruitment of intracellular adaptor proteins, including insulin receptor substrate 1, to the receptor 263	
complex, and activation of Phosphatidylinositol 3-kinase (PI3K). The resulting phosphoinositol 264	
triphosphate promotes phosphorylation of protein kinase B/Akt, which then phosphorylates various 265	
substrates that orchestrate the various physiological effects of the two hormones. Increased glucose 266	
disposal is mediated predominantly through phosphorylation of Akt substrate of 160kDa (TBC1D4) 267	
and TBC1D1, and thus movement of GLUT4-containing vesicles to the plasma membrane (Cartee 268	
and Funai 2009), as well as disinhibition of glycogen synthesis by phosphorylation of glycogen 269	
synthase kinase 3. Akt-mediated activation of mTOR, and thus p70S6 kinase and eukaryotic 270	
translation initiation factor 4E-binding protein 1 (4E-BP1), is responsible for protein synthesis, and 271	
indeed amino acid-stimulated protein synthesis is also mediated through activation of mTOR. In 272	
parallel, Akt-mediated inhibition of forkhead transcription factor (FOXO) activity reduces expression 273	
of the E3 ubiquitin ligases that are principally responsible for mediating atrophy (atrogin-1/ muscle 274	
atrophy F-box and muscle RING finger 1) (Schiaffino, et al. 2013). 275	
Consequently, activation of proximal PI3K pathways would be expected to have dual positive effects 276	
on muscle size and metabolism. This is clearly illustrated by muscle overexpression of Akt in rodents, 277	
which causes both muscle hypertrophy  and increased glucose disposal per unit muscle mass, with the 278	
predominant effects determined by the isoform used (Akt 1 versus Akt 2-predominant effects, 279	
respectively) (Bodine, et al. 2001b; Cleasby, et al. 2007). Furthermore, defects in both components of 280	
the pathway were identified in leptin receptor-null (db/db) mice and obese Zucker rats. Treatment 281	
with the insulin sensitising thiazolidinedione drug rosiglitazone also led to an improvement in muscle 282	
mass, leading to the suggestion that IR per se could causes muscle wasting through suppression of 283	
PI3K/Akt signalling (Katta, et al. 2010; Wang, et al. 2006). However, it is equally plausible that 284	
activation of the Akt-mTOR cellular signalling pathways following peroxisome proliferator-activated 285	
receptor (PPAR)γ stimulation by rosiglitazone impacts positively on both IR and muscle mass. The 286	
physiological relevance of this is unclear, as impairment of the Akt-mTOR pathway in muscle does 287	




AMP-activated protein kinase 290	
AMP-activated protein kinase (AMPK) is a cellular energy sensor that is activated by an increased 291	
AMP:ATP ratio, leading to increased glucose and fatty acid uptake and oxidation in skeletal muscle 292	
(Koh, et al. 2008). It plays a major role in coordinating energy use during exercise in muscle, but also 293	
mediates the longer term effects of exercise, through mitochondrial biogenesis. This process is 294	
initiated by AMPK-mediated activation of silent mating-type information regulator 2 homolog 1 295	
(SIRT1) and PPAR coactivator-1α (PGC1α) (Mounier, et al. 2015). AMPK has been extensively 296	
studied as a potential molecular target for the development of novel therapies for T2D (Coughlan, et 297	
al. 2014) and recent work has identified an additional role for AMPK in muscle turnover/plasticity. It 298	
can protect against age-related functional and mitochondrial impairment by promoting myocyte 299	
macroautophagy, an essential process for cellular maintenance (Bujak, et al. 2015). AMPK likely 300	
mediates the effects of adiponectin to promote macroautophagy (Liu, et al. 2015), which likely at least 301	
partly mediates this adipokine’s insulin-sensitising effect in muscle (Patel, et al. 2012). However, the 302	
effects of AMPK on muscle mass appear less favourable. A study of aging rodents showed an inverse 303	
relationship between activating AMPK phosphorylation and load-induced hypertrophy (Thomson and 304	
Gordon 2005). Furthermore, AMPK stimulates myofibrillar protein degradation through increased 305	
FOXO expression (Nakashima and Yakabe 2007) and causes downregulation of the mTOR pathway, 306	
thus restricting protein synthesis (Bolster, et al. 2002). In addition, liver kinase b1 (Lkb1), one of 307	
AMPK’s upstream kinases, has been shown to limit differentiation of satellite cells (stem cells present 308	
in adult skeletal muscle) through the same mechanism (Shan, et al. 2014). Thus, further studies are 309	
necessary to ascertain whether AMPK activation would have a net beneficial effect in individuals 310	
with both IR and sarcopenia. 311	
Myostatin 312	
Myostatin (MSTN) is now well-established as a central determinant of muscle size and mass, as 313	
demonstrated by the pronounced increases in muscle mass caused by gene-inactivating mutations in 314	
mice (McPherron, et al. 1997) and by naturally occurring genetic loss of function variants in several 315	
domestic species (Hill, et al. 2010). Consistent with this, its expression has also been shown to be 316	
increased in sarcopenia in some studies (Leger, et al. 2008), but this has not been a universal finding 317	
(Ratkevicius, et al. 2011). 318	
However, in addition to its effects on muscle mass, MSTN deficiency has more recently been shown 319	
to have beneficial effects on metabolism, adiposity and insulin sensitivity. Both MSTN-null mice 320	
(Guo, et al. 2009) and mice treated either with the soluble MSTN receptor Activin Receptor IIb 321	
(Akpan, et al. 2009), which sequesters the mature peptide in the plasma, or the natural inhibitor 322	
follistatin-like 3 (Brandt, et al. 2015), show increased muscle glucose utilisation and insulin 323	
sensitivity, associated with increased lean mass and decreased fat mass.  324	
Genetic or pharmacological inactivation of MSTN increases activation of AMPK (Zhang, et al. 2011), 325	
increases lipolysis and fatty acid oxidation in peripheral tissues, and also increases the expression of 326	
brown adipocyte markers in white adipose tissue (Zhang, et al. 2012), providing a number of potential 327	
mechanisms for its metabolic activity. Importantly, we have also recently shown that short-term local 328	
impairment of MSTN action in rats by overexpression of the myostatin propeptide and sequestration 329	
of the active peptide enhances skeletal muscle glucose disposal to a greater extent than would be 330	
expected due to increased muscle mass alone, implying that additive or synergistic mechanisms are in 331	
operation. The associated increase in glucose transporter (GLUT1 and GLUT4) protein levels may 332	
underpin the metabolic effects observed (Cleasby et al. 2014). 333	
A number of modalities utilising inhibition of MSTN activity as a therapeutic approach have not yet 334	
borne fruit, although antisense-mediated destructive exon skipping is currently being evaluated. This 335	
has shown some promise in preserving muscle mass in a mouse model of Duchenne muscular 336	




Urocortins (Ucns) are neuropeptide ligands for the corticotropin-releasing factor receptor 2 (CRFR2) 339	
that are expressed not only in the central nervous system, but also in peripheral metabolic tissues. 340	
There are particularly high levels of Ucn2 and CRFR2 in skeletal muscle (Chen, et al. 2006), implying 341	
that these ‘stress regulators’ play a role in muscle physiology. Furthermore, CRFR2 expression was 342	
reduced on average by 71% and 92% in soleus and tibialis cranialis muscles, respectively, of aged 343	
mice (24 vs 3 month old; n=6, p<0.001). 344	
Global knockout of either Ucn2 or CRFR2 produced mice that were resistant to diet-induced obesity 345	
and IR (Bale, et al. 2003; Chen et al. 2006), the former also demonstrating increased muscle mass. 346	
Interestingly however, global overexpression of Ucn3 also resulted in mice with marked muscular 347	
hypertrophy. These mice had increased IGF1 expression in muscle and also resisted the increased 348	
adiposity and metabolic abnormalities associated with feeding a high fat diet, despite the lack of 349	
endogenous muscle Ucn3 expression (Jamieson, et al. 2011). In order to dissect the muscle-350	
autonomous component of this phenotype further and to indicate whether CRFR2 might have 351	
potential as a therapeutic target, we performed short-term overexpression of Ucn3 in rat muscle and 352	
showed increased glucose disposal, associated with elevated levels of glucose transporter expression, 353	
and phosphorylation of both AMPK and insulin signalling intermediates, before any increased muscle 354	
mass was detectable (Roustit, et al. 2014). Thus, a strategy to target CRFR2 also may have potential 355	
to improve muscle mass and metabolism additively. 356	
Vitamin D 357	
There has recently been renewed interest in potential novel roles for vitamin D (VitD), including in 358	
the maintenance of muscle mass and insulin sensitivity, which has been provoked in part by the 359	
identification of a high prevalence of VitD deficiency among adults (Bates, et al. 2011). Profound 360	
dietary insufficiency leads to impaired muscle strength as a result of hypophosphataemia in rats 361	
(Schubert and DeLuca 2010). However, epidemiological and intervention studies in humans have 362	
yielded contradictory results with regard to the role of VitD in muscle mass/function and metabolic 363	
endpoints. For example, insulin sensitivity has been reported to be either improved or unaffected by 364	
VitD supplementation (Talaei, et al. 2013; Wongwiwatthananukit, et al. 2013). VitD supplementation 365	
was reported to increase muscle fibre size in immobile older women (Ceglia, et al. 2013), but a recent 366	
systematic review of studies showed a benefit of supplementation for individuals with VitD 367	
deficiency at the start of the trial in terms of improved muscle strength, but not in muscle mass or 368	
power (maximum force generated in minimum time) (Beaudart, et al. 2014). These contradictory 369	
findings might be a result of insufficient study power and imprecise subject selection in many 370	
instances.  371	
Attempts to explain a hypothesised role for VitD in muscle on a molecular level have been few to 372	
date, but knockout of the VitD receptor (VDR) in mice resulted in reduced muscle size, impaired 373	
motor activity (Burne, et al. 2006) and abnormal muscle development (Endo, et al. 2003), In addition, 374	
VDR-null mice are leaner (Narvaez, et al. 2009), possibly due to increased uncoupling protein 375	
expression (Wong, et al. 2009), but conversely have recently been shown to be insulin resistant, a 376	
phenotype that was shown to be mediated through increased muscle FOXO1 activation (Chen, et al. 377	
2015). Further work is needed to define the mechanistic links between VitD, the VDR and aging-378	
related phenotypes. 379	
 380	
Additional therapeutic perspectives 381	
Sarcopenia (Baumgartner, et al. 1999; Genton, et al. 2011; Lee, et al. 2007; Park, et al. 2010; Raguso, 382	
et al. 2006; Scott, et al. 2011; Szulc, et al. 2004) and SO (Ryu et al. 2013) have been associated with 383	
low levels of physical activity in both cross-sectional and longitudinal studies, while exercise-based 384	
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interventions are well established to improve both muscle mass and performance (Skelton, et al. 1995; 385	
Vincent, et al. 2002) and insulin sensitivity (Fujita et al. 2007) in aged individuals. However, it is 386	
clear that these interventions are of more use in the prevention, rather than treatment of sarcopenia  or 387	
SO and metabolic dysfunction, as elderly individuals are often too frail to undertake the degree of 388	
exercise required to achieve a beneficial effect (Wolfe 2006), while they may also suffer from 389	
anabolic resistance. 390	
In addition, it is clear that a profound reduction in dietary energy intake can have a remarkable effect 391	
to alleviate IR and T2D (Steven and Taylor 2015). However, the inevitable lean tissue mass that is 392	
lost using this approach alone renders it undesirable in the already sarcopenic elderly, unless 393	
concurrent exercise or appropriate nutritional supplementation is undertaken (Verreijen, et al. 2015; 394	
Yoshimura, et al. 2014). Although a comprehensive assessment of dietary approaches is outwith the 395	
scope of this review, it is clear that motivation and compliance can frequently be a major limiting 396	
factor in the success of such lifestyle interventions (Evangelista, et al. 2003). 397	
In terms of current pharmacotherapy, androgen replacement in hypogonadal men is effective in 398	
increasing muscle mass, but its use is as yet unproven in normal aging individuals, and is 399	
accompanied by undesirable side-effects (Giannoulis, et al. 2012). Nevertheless, androgen use may 400	
also be associated with an improvement in insulin sensitivity (Traish, et al. 2009). The development 401	
of selective androgen receptor-modulating therapies (SARMs) may help mitigate many of these side 402	
effects. Preclinical and Phase II trials of candidate drugs have demonstrated beneficial effects upon 403	
insulin sensitivity as well as on muscle mass and strength (Dalton, et al. 2011; Gao, et al. 2005; Min, 404	
et al. 2009). 405	
One possible novel therapeutic approach might be to stimulate satellite cell activity and thus myofibre 406	
regeneration or replacement (Bernet et al. 2014), with the intention not only of improving muscle 407	
strength, but capacity for glucose disposal. However, satellite cell ablation in adult mice did not affect 408	
age-related sarcopenia in a recent study (Fry et al. 2015), implying that strategies aimed at stimulating 409	
their fusion or proliferation may not be effective. Furthermore, chronic activation of pathways 410	
triggering muscle growth, such as the IGF1-Akt pathway (Bellacosa, et al. 2005), involves the 411	
activation of known oncogenes, and thus the risk of tumour development. 412	
PGC1α is another molecular target that might have promise as a candidate for alleviation of both 413	
metabolic inefficiency and sarcopenia. This molecule is regarded as a key mediator of the beneficial 414	
effects of endurance exercise. Increased expression of PGC1α in muscle improves metabolic fitness 415	
and prevents sarcopenia in aging mice (Wenz, et al. 2009), although it is unclear whether it promotes 416	
muscle strength in addition. Activation of PGC1α has been shown to result in increased secretion of a 417	
novel hormone, irisin, which alleviates IR in mice (Bostrom, et al. 2012), although the significance of 418	
this finding for human biology has been questioned (Raschke, et al. 2013; Timmons, et al. 2012). 419	
Nevertheless, there is much interest in designing an “exercise mimetic” drug, based on such a 420	
molecular target, which would both improve muscle mass/function and metabolism, to tackle obesity-421	
related metabolic disorders. However, it would seem unlikely that an approach aimed at targeting a 422	
single mediator would be successful in human trials.  423	
 424	
Conclusions and challenges for the future 425	
This review has discussed current knowledge of the physiological and molecular mechanisms that 426	
govern both atrophy/sarcopenia and insulin resistance in skeletal muscle. We have aimed to highlight 427	
potential common ground between these mechanisms that could point to future development of novel 428	
therapies for SO in the elderly. 429	
A number of challenges remain to address the deficiencies in our knowledge of this syndrome: 430	
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1. To establish a robust clinical definition of SO to enhance study design and thus permit improved 431	
comparability between clinical studies. 432	
2. To establish whether sarcopenia and muscle insulin resistance are in fact inevitable co-morbidities, 433	
given the substantial overlap in the molecular pathways that are dysregulated in each. 434	
3. To develop a more suitable animal model for SO to permit more practical mechanistic studies and 435	
preclinical therapeutic trials. 436	
4. To further elucidate the key molecular pathways mediating both pathologies, permitting 437	
identification of molecular targets suitable for the development of combined therapies. 438	
Addressing these priorities will hopefully provide a sounder footing from which to attempt more 439	
rational treatment of this common and debilitating condition. 440	
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Figure 1: Clinical characterisation of sarcopenic obesity. 894	
Sarcopenia, obesity and insulin resistance increase in prevalence with advancing age. When 895	
individuals display several of the clinical signs listed, they may be defined as showing sarcopenic 896	
obesity. Dotted arrows indicate likely causative relationships and suggest that insulin resistance may 897	
be central to the syndrome. 898	
Figure 2: Insulin resistance and “Anabolic resistance” in skeletal muscle and the role of 899	
intramyocellular lipid deposition. 900	
A- Normal muscle of young adult. Protein synthesis predominates over proteolysis under stimulation 901	
by supply of essential amino acids and insulin. Optimal insulin sensitivity favours glucose disposal 902	
and oxidation of lipids. B- Muscle of aged adult with sarcopenic obesity. Obesity-associated increases  903	
in intramyocellular lipid deposition, among other factors, causes impaired insulin signalling, protein 904	
synthesis and glucose metabolism. There is also a reduced anabolic response to exercise, amino acids 905	
and insulin. However, the extent of this resistance to insulin on protein, lipid and glucose metabolism 906	
varies between individuals. Straight arrows: metabolite flux. Broken straight arrows: reduced 907	
metabolite flux. Filled curved arrows: stimulatory effect. Open curved arrows: inhibitory effect. 908	
Figure 3: Roles of selected candidate molecular mediators in skeletal muscle glucose and protein 909	
metabolism. 910	
Published effects of insulin, insulin-like growth factor 1 (IGF1), amino acids, myostatin, urocortins 911	
and vitamin D on signalling pathways and effector machinery (glucose transporters, mitochondrial 912	
function, translation and activation of E3 ubiquitin ligases) relating to glucose and protein 913	
metabolism, as discussed in the text. Unmarked arrow: movement of molecules. Arrow with “+”: 914	
direct stimulatory effect on expression or activity. Arrow with “-”: direct inhibitory effect on 915	
expression or activity. Broken arrow: indirect effect. P indicates phosphorylation. Act2BR- Activin 916	
2B Receptor. AMPK- AMP-activated protein kinase. AS160- Akt substrate of 160kDa. CRFR2- 917	
corticotropin releasing factor receptor 2. FOXO- forkhead transcription factor. GLUT4- Glucose 918	
transporter 4. IGF1R- IGF1 receptor. NFκB- Nuclear Factor κB. PGC1α- peroxisome proliferator-919	
activated receptor coactivator 1α. MAPK- mitogen-activated protein kinase. mTOR- mammalian 920	
target of rapamycin. PI3K- phosphoinositol 3-kinase. SIRT1- sirtuin 1. VDR- vitamin D receptor. 921	
Figure 1: Clinical characterisation of sarcopenic obesity. 
Sarcopenia, obesity and insulin resistance increase in prevalence with advancing age. When individuals display several 
of the clinical signs listed, they may be defined as showing sarcopenic obesity. Dotted arrows indicate likely causative 















Figure 2: Insulin resistance and “Anabolic resistance” in skeletal muscle and the role of intramyocellular lipid 
deposition. A- Normal muscle of young adult. Protein synthesis predominates over proteolysis under stimulation by 
supply of essential amino acids and insulin. Optimal insulin sensitivity favours glucose disposal and oxidation of 
lipids. B- Muscle of aged adult with sarcopenic obesity. Obesity-associated increases  in intramyocellular lipid 
deposition, among other factors, causes impaired insulin signalling, protein synthesis and glucose metabolism. There is 
also a reduced anabolic response to exercise, amino acids and insulin. However, the extent of this resistance to insulin 
on protein, lipid and glucose metabolism varies between individuals. Straight arrows: metabolite flux. Broken straight 





























Figure 3: Roles of selected candidate molecular mediators in skeletal muscle glucose and protein metabolism. 
Published effects of insulin, insulin-like growth factor 1 (IGF1), amino acids, myostatin, urocortins and vitamin D on 
signalling pathways and effector machinery (glucose transporters, mitochondrial function, translation and activation of 
E3 ubiquitin ligases) relating to glucose and protein metabolism, as discussed in the text. Unmarked arrow: movement 
of molecules. Arrow with “+”: direct stimulatory effect on expression or activity. Arrow with “-”: direct inhibitory 
effect on expression or activity. Broken arrow: indirect effect. P indicates phosphorylation. Act2BR- Activin 2B 
Receptor. AMPK- AMP-activated protein kinase. AS160- Akt substrate of 160kDa. CRFR2- corticotropin releasing 
factor receptor 2. FOXO- forkhead transcription factor. GLUT4- Glucose transporter 4. IGF1R- IGF1 receptor. NFκB- 
Nuclear Factor κB. PGC1α- peroxisome proliferator-activated receptor coactivator 1α. MAPK- mitogen-activated 
protein kinase. mTOR- mammalian target of rapamycin. PI3K- phosphoinositol 3-kinase. SIRT1- sirtuin 1. VDR- 
vitamin D receptor. 
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